We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Review May Prompt Panel to Propose Stricter Standards for Amgen’s Aranesp
FDA Review May Prompt Panel to Propose Stricter Standards for Amgen’s Aranesp
October 14, 2010
FDA reviewers in a report released Thursday express doubt that Amgen’s Aranesp is a safe and effective treatment to raise hemoglobin (Hb) levels in patients with anemia caused by chronic kidney disease.